Regeneron Pharmaceuticals Plummets to 196th in Trading Volume Ranking as Stock Price Falls for Fourth Consecutive Day

On April 8, 2025, Regeneron Pharmaceuticals (REGN) experienced a significant decline, with its trading volume reaching $643 million, marking a 33.18% decrease from the previous day. This drop placed Regeneron at the 196th position in terms of trading volume for the day. The stock price of Regeneron also fell by 2.79%, marking the fourth consecutive day of decline, with a total decrease of 11.00% over the past four days.

Analysts have given Regeneron Pharmaceuticals a consensus rating of "Buy," with an average 12-month price target of $984.84. This target represents a substantial increase from the current stock price, indicating a strong bullish sentiment among analysts. The company's stock has been the subject of various price target adjustments, with Jefferies recently lowering its target to $936 from $1,120 while maintaining a "Buy" rating.

Regeneron Pharmaceuticals is known for its innovative approach to drug discovery and development, focusing on areas such as ophthalmology, oncology, and inflammatory diseases. The company's pipeline includes several promising candidates that could drive future growth and contribute to the positive analyst sentiment.